ended8월 20일· 1 sources
mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
Why it matters
Pharmaceutical partners Moderna and Merck announced on Wednesday that their novel mRNA-based vaccine—individually tailored to target a patient’s unique cancer mutations—was effective in a late-stage c...
1
Sources
+0
24h
—
Growth
6d
Active